PURPOSE: To determine the maximum tolerated dose (MTD) of carboplatin with autologous hematopoietic stem-cell rescue, in children with poor-prognosis brain tumors. PATIENTS AND METHODS: A previously determined dose of cyclophosphamide with stem-cell rescue was used as a first course. In a second course, carboplatin was given for 3 days with stem-cell rescue to 20 children. The starting dose of carboplatin was 400 mg/m2/day with increments of 75 mg/m2/day in subsequent cohorts. Toxicity and tumor response were recorded. RESULTS: There were two grade IV toxicities at the dose level of 775 mg/m2/day. There were no toxic deaths. Thus, the MTD of carboplatin was 700 mg/m2/day for 3 days. There were six complete responses (33%, 95% confidence interval [CI], 13-59%), two partial responses (11%; 95% CI, 1-35%), four with stable diseases (22%; 95% CI, 6-48%) and six progressed (33%; 95% CI, 13-59%) out of 18 assessable. Seven of the eight responses were in primitive neuroectodermal tumors (PNETs) or Germinomas. One child with a metastatic anaplastic astrocytoma had a CR. The median duration of tumor response was 10 months (range: 1.5-87 months) with two children disease free at 66 and 87 months. Actuarial survival is 21%. Median follow-up of survivors is 35 months (range: 15-87 months). CONCLUSION: The MTD of carboplatin with stem-cell rescue is 700 mg/m2/day for 3 days. Sequential stem-cell supported cyclophosphamide and carboplatin was tolerable in children with brain tumors and produced responses in PNETs and Germinomas.
PURPOSE: To determine the maximum tolerated dose (MTD) of carboplatin with autologous hematopoietic stem-cell rescue, in children with poor-prognosis brain tumors. PATIENTS AND METHODS: A previously determined dose of cyclophosphamide with stem-cell rescue was used as a first course. In a second course, carboplatin was given for 3 days with stem-cell rescue to 20 children. The starting dose of carboplatin was 400 mg/m2/day with increments of 75 mg/m2/day in subsequent cohorts. Toxicity and tumor response were recorded. RESULTS: There were two grade IV toxicities at the dose level of 775 mg/m2/day. There were no toxic deaths. Thus, the MTD of carboplatin was 700 mg/m2/day for 3 days. There were six complete responses (33%, 95% confidence interval [CI], 13-59%), two partial responses (11%; 95% CI, 1-35%), four with stable diseases (22%; 95% CI, 6-48%) and six progressed (33%; 95% CI, 13-59%) out of 18 assessable. Seven of the eight responses were in primitive neuroectodermal tumors (PNETs) or Germinomas. One child with a metastatic anaplastic astrocytoma had a CR. The median duration of tumor response was 10 months (range: 1.5-87 months) with two children disease free at 66 and 87 months. Actuarial survival is 21%. Median follow-up of survivors is 35 months (range: 15-87 months). CONCLUSION: The MTD of carboplatin with stem-cell rescue is 700 mg/m2/day for 3 days. Sequential stem-cell supported cyclophosphamide and carboplatin was tolerable in children with brain tumors and produced responses in PNETs and Germinomas.
Authors: A E Evans; R D Jenkin; R Sposto; J A Ortega; C B Wilson; W Wara; I J Ertel; S Kramer; C H Chang; S L Leikin Journal: J Neurosurg Date: 1990-04 Impact factor: 5.115
Authors: M L Graham; J E Herndon; J R Casey; S Chaffee; G H Ciocci; J P Krischer; J Kurtzberg; M J Laughlin; D C Longee; J F Olson; N Paleologus; C N Pennington; H S Friedman Journal: J Clin Oncol Date: 1997-05 Impact factor: 44.544
Authors: V Papadakis; I J Dunkel; L D Cramer; E Kramer; E Papadopoulos; S Goldman; R J Packer; M Willoughby; D Baker; J Garvin; S Strandjord; P Coccia; A M Kaplan; M Klemperer; J L Finlay Journal: Bone Marrow Transplant Date: 2000-07 Impact factor: 5.483
Authors: I J Dunkel; J H Garvin; S Goldman; L J Ettinger; A M Kaplan; M Cairo; H Li; J M Boyett; J L Finlay Journal: J Neurooncol Date: 1998-03 Impact factor: 4.130
Authors: V M Santana; M J Schell; R Williams; L C Bowman; E I Thompson; M K Brenner; J Mirro Journal: Bone Marrow Transplant Date: 1992-11 Impact factor: 5.483
Authors: J H Wisoff; J M Boyett; M S Berger; C Brant; H Li; A J Yates; P McGuire-Cullen; P A Turski; L N Sutton; J C Allen; R J Packer; J L Finlay Journal: J Neurosurg Date: 1998-07 Impact factor: 5.115
Authors: Roger J Packer; James G Gurney; Judy A Punyko; Sarah S Donaldson; Peter D Inskip; Marilyn Stovall; Yutaka Yasui; Ann C Mertens; Charles A Sklar; H Stacy Nicholson; Lonnie K Zeltzer; Joseph P Neglia; Leslie L Robison Journal: J Clin Oncol Date: 2003-09-01 Impact factor: 50.717
Authors: Eduard H Panosyan; Alan K Ikeda; Vivian Y Chang; Dan R Laks; Charles L Reeb; La Vette Bowles; Joseph L Lasky; Theodore B Moore Journal: J Transplant Date: 2011-04-14
Authors: Jun Eun Park; Joseph Kang; Keon Hee Yoo; Ki Woong Sung; Hong Hoe Koo; Do Hoon Lim; Hyung Jin Shin; Hyoung Jin Kang; Kyung Duk Park; Hee Young Shin; Il Han Kim; Byung-Kyu Cho; Ho Joon Im; Jong Jin Seo; Hyeon Jin Park; Byung-Kiu Park; Hyo Seop Ahn Journal: J Korean Med Sci Date: 2010-07-21 Impact factor: 2.153
Authors: Hee Jo Baek; Hyeon Jin Park; Ki Woong Sung; Soo Hyun Lee; Jung Woo Han; Kyung Nam Koh; Ho Joon Im; Hyoung Jin Kang; Kyung Duk Park Journal: J Neurooncol Date: 2013-07-04 Impact factor: 4.130